ACHL — Achilles Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $60.83m
- -$25.22m
- 20
- 45
- 78
- 46
Annual cashflow statement for Achilles Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14 | -33.2 | -61.1 | -71.2 | -69.7 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.733 | 2.99 | 6.48 | 14.5 | 6.33 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.19 | 4.19 | -7.93 | -6.33 | 9.97 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -14.1 | -25.3 | -59.3 | -59.5 | -48.4 |
| Capital Expenditures | -0.942 | -11.8 | -7.63 | -7.51 | -1.1 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.942 | -11.8 | -7.63 | -7.51 | -1.1 |
| Financing Cash Flow Items | 0 | -0.121 | 0 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 93.6 | 114 | 161 | 0.001 | 0.009 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 86.9 | 80.3 | 88.5 | -93 | -41.8 |